| Field | Specification |
|---|---|
| UniProt # | |
| Applications | |
| Sensitivity | |
| Detection range | |
| Detection method | |
| Assay time | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
This ELISA kit applies to the in vitro quantitative determination of Human S100B concentrations in serum, plasma and other biological fluids.
Assay Principle
This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human S100B. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human S100B and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human S100B, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human S100B. You can calculate the concentration of Human S100B in the samples by comparing the OD of the samples to the standard curve.
Performance Specifications
| Sensitivity | 18.75 pg/mL |
|---|---|
| Detection Range | 31.25-2000 pg/mL |
| Total Assay Time | 3 h 30 min |
| Compatible Sample Types | Serum, plasma and other biological fluids |
| Species Reactivity | Human |
| Detection Method | Sandwich |
| Precision (CV) | Both intra-CV and inter-CV are < 10%. |
| Recovery Rate | 80%-120% |
| Storage | 2-8℃,12 months |
✓ Research-Grade Validation
Specificity
This kit recognizes Human S100B in samples. No significant cross-reactivity or interference between Human S100B and analogues was observed
Safety & Regulatory
Handle reagents in accordance with institutional biosafety guidelines. Refer to the Safety Data Sheet (SDS) for complete hazard and handling information. Contains components that may require special disposal procedures per local regulations.
This kit is validated for use with Serum, plasma and other biological fluids. For unlisted matrices (e.g., tissue lysate, urine), perform a spike-and-recovery experiment to confirm assay performance before generating reportable data. Sample dilution in the kit's provided diluent is recommended to minimize matrix interference.
The minimum detectable concentration (sensitivity) of this kit is 18.75 pg/mL. Values below this threshold should be reported as below the limit of detection (<LOD) and should not be extrapolated from the standard curve.
The total assay time from sample addition to absorbance reading is approximately 3 h 30 min, including all incubation, wash, and substrate steps. Hands-on time is typically 1–2 hours; most steps involve passive plate incubation. Plan the assay as a single uninterrupted session for best results.
Standard components of this Sandwich ELISA Kit typically include: pre-coated microplate (96-well strip format), lyophilized or liquid recombinant S100B standard, detection antibody, streptavidin-HRP conjugate, TMB substrate, stop solution, wash buffer concentrate, and sample/standard diluent. Refer to the kit insert or datasheet for the exact component list and storage requirements.
This kit uses colorimetric (TMB/HRP) detection and requires a standard microplate absorbance reader capable of measuring at 450 nm. A reference wavelength of 570 nm or 630 nm is recommended to reduce background. No specialized fluorescence or luminescence reader is needed. Ensure the instrument is calibrated and the plate is clean and free of condensation before reading.
Tissue samples may contain endogenous or exogenous proteases during processing, leading to degradation of extracted proteins. Therefore, it's necessary to add protease inhibitors during processing to ensure the integrity of target proteins. If customers can keep samples cold and handle them quickly during processing, omitting the protease inhibitor may not have a significant effect. After preparation, samples should be tested promptly or immediately aliquoted and frozen at -20°C or -80°C.
What is the range of enzyme activity of your IL-2 freeze-dried powder
What is the principle of adding stop solution to stop color reaction in ELISA experiment?
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin-LL37, and ICAM1 (2021) Nutrients. 10.3390/nu13114047
Plasma biomarkers of brain injury in COVID-19 patients with neurological symptoms (2022) JOURNAL OF THE NEUROLOGICAL SCIENCES. 10.1016/j.jns.2022.120324
Examination of Cognitive Function, Neurotrophin Concentrations, and both Brain and Systemic Inflammatory Markers Following a Simulated Game of American Football (2022) JOURNAL OF STRENGTH AND CONDITIONING RESEARCH. 10.1519/JSC.0000000000004218
The impact of manual lymphatic drainage on postoperative inflammatory-stress response and functional recovery in elderly hip fracture patients (2026) EXPERIMENTAL GERONTOLOGY. 10.1016/j.exger.2026.113139
Neurofilament light chain and S100B serum levels are associated with disease severity and outcome in patients with aneurysmal subarachnoid hemorrhage (2022) Frontiers in Neurology. 10.3389/fneur.2022.956043
Can the Prognosis of COVID-19 Disease Be Determined by Fecal Markers and Cytokines? (2022) JOURNAL OF INTERFERON AND CYTOKINE RESEARCH. 10.1089/jir.2022.0098
The elastin-derived peptide (VGVAPG) activates autophagy in neuroblastoma (SH-SY5Y) cells via peroxisome proliferator-activated receptor gamma (PPARγ) (2023) MOLECULAR AND CELLULAR NEUROSCIENCE. 10.1016/j.mcn.2023.103902
Glymphatic Imaging and Serum Glial Biomarkers in Children with Obstructive Sleep Apnea (2026) SLEEP MEDICINE. 10.1016/j.sleep.2026.108986
Novel Biomarkers for Prognostic Assessment of Patients with Acute Exacerbation of COPD in the Emergency Department—Tools to Enhance the Quality of Care in Critical Patient Management (2026) Diagnostics. 10.3390/diagnostics16010122
Effect of Astragalus Membranaceus on Neurological Function in Acute aneurysmal subarachnoid hemorrhage patients with high inflammation: A Preliminary Randomized, Double-Blind, Placebo-Controlled Clinical Trial (2024) Journal of Traditional and Complementary Medicine. 10.1016/j.jtcme.2024.04.002
Short-Term Postoperative Cognitive Dysfunction and Inflammatory Response in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Pilot Study (2017) MEDIATORS OF INFLAMMATION. 10.1155/2017/3605350
Prediction of Normal Tissue Complication Probability (NTCP) After Radiation Therapy Using Imaging and Molecular Biomarkers and Multivariate Modelling (2023) JOURNAL OF MOLECULAR NEUROSCIENCE. 10.1007/s12031-023-02136-9
A Retrospective Assessment of Changes in Stroke Risk-Related Biomarkers in Individuals with Prediabetes from Durban, South Africa: Preliminary Findings (2025) CURRENT ISSUES IN MOLECULAR BIOLOGY. 10.3390/cimb47110884
Unique content of breastmilk: neurotrophic growth factors in breastmilk at 2 years and beyond (2024) EUROPEAN JOURNAL OF PEDIATRICS. 10.1007/s00431-024-05732-y
Changes of biochemical biomarkers in the serum of children with convulsion status epilepticus: a prospective study (2022) BMC Neurology. 10.1186/s12883-022-02686-2
CCL4L2 is a potential biomarker for differentiating central and peripheral vertigo (2025) Frontiers in Integrative Neuroscience. 10.3389/fnint.2025.1620845
Enteroviral meningitis reduces CSF concentration of Aβ42, but does not affect markers of parenchymal damage (2019) EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 10.1007/s10096-019-03569-0
Association of BDNF levels with IQ: comparison of S100B and BDNF levels in typically developing children and subjects with neurologically normal nonsyndromic intellectual disability (2021) JOURNAL OF INTELLECTUAL DISABILITY RESEARCH. 10.1111/jir.12896
The elevation of S100B and downregulation of circulating miR-602 in the sera of ischemic stroke (IS) patients: the emergence of novel diagnostic and prognostic markers (2020) NEUROLOGICAL SCIENCES. 10.1007/s10072-020-04323-7
Investigation of the Acute Effects of Two Different Preoxygenation Methods on Neurodegenerative Biomarkers in Laparoscopic Cholecystectomy Surgery (2025) Medicina-Lithuania. 10.3390/medicina61020167
Changes in amplitude-integrated electroencephalography, neuron-specific enolase, and S100B in neonates with brain injury induced by neonatal hyperbilirubinemia and their significance (2021) BRAIN INJURY. 10.1080/02699052.2021.1931449
Effect of pre-infusion of hypertonic saline on postoperative delirium in geriatric patients undergoing shoulder arthroscopy: a randomized controlled trial (2023) BMC Anesthesiology. 10.1186/s12871-023-02340-5
Serum NSE and S100B protein levels for evaluating the impaired consciousness in patients with acute carbon monoxide poisoning (2021) MEDICINE. 10.1097/MD.0000000000026458
The effects of hyperbaric oxygen therapy on neuroprotection and recovery after brain resuscitation (2024) INTERNATIONAL JOURNAL OF NEUROSCIENCE. 10.1080/00207454.2024.2346172
Targeting Mitochondrial and Brain Injury Markers in Acquired Brain Injuries: A Randomized, Double-Blind, Placebo-Controlled Study with Melatonin (2021) Advanced Pharmaceutical Bulletin. 10.34172/apb.2022.013
